258 related articles for article (PubMed ID: 33363734)
1. NKG2D and MICA/B shedding: a 'tag game' between NK cells and malignant cells.
Xing S; Ferrari de Andrade L
Clin Transl Immunology; 2020; 9(12):e1230. PubMed ID: 33363734
[TBL] [Abstract][Full Text] [Related]
2. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
3. A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells.
Guo C; Dong M; Wang X; Yu J; Jin X; Cheng S; Cui F; Qian Y; Bao Q; Zhi L; Niu Z; Li M; Zhu W
Biochem Biophys Res Commun; 2024 May; 710():149918. PubMed ID: 38598902
[TBL] [Abstract][Full Text] [Related]
4. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
5. MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner.
Du C; Bevers J; Cook R; Lombana TN; Rajasekaran K; Matsumoto M; Spiess C; Kim JM; Ye Z
J Immunother Cancer; 2019 Aug; 7(1):207. PubMed ID: 31387641
[TBL] [Abstract][Full Text] [Related]
6. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.
Bilotta MT; Abruzzese MP; Molfetta R; Scarno G; Fionda C; Zingoni A; Soriani A; Garofalo T; Petrucci MT; Ricciardi MR; Paolini R; Santoni A; Cippitelli M
FASEB J; 2019 Aug; 33(8):9489-9504. PubMed ID: 31125275
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract][Full Text] [Related]
8. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA.
Holdenrieder S; Stieber P; Peterfi A; Nagel D; Steinle A; Salih HR
Cancer Immunol Immunother; 2006 Dec; 55(12):1584-9. PubMed ID: 16636811
[TBL] [Abstract][Full Text] [Related]
9. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
[TBL] [Abstract][Full Text] [Related]
10. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.
Ferrari de Andrade L; Tay RE; Pan D; Luoma AM; Ito Y; Badrinath S; Tsoucas D; Franz B; May KF; Harvey CJ; Kobold S; Pyrdol JW; Yoon C; Yuan GC; Hodi FS; Dranoff G; Wucherpfennig KW
Science; 2018 Mar; 359(6383):1537-1542. PubMed ID: 29599246
[TBL] [Abstract][Full Text] [Related]
11. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
12. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
13. NK Cell Interaction With Platelets and Myeloid Cells in the Tumor Milieu.
Maurer S; Ferrari de Andrade L
Front Immunol; 2020; 11():608849. PubMed ID: 33424862
[TBL] [Abstract][Full Text] [Related]
14. Ethanol-dependent expression of the NKG2D ligands MICA/B in human cell lines and leukocytes.
Streltsova MA; Klinkova AV; Kuchukova AA; Kadin AY; Kanevskiy LM; Kovalenko EI
Biochem Cell Biol; 2017 Apr; 95(2):280-288. PubMed ID: 28177768
[TBL] [Abstract][Full Text] [Related]
15. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.
Schmiedel D; Mandelboim O
Front Immunol; 2018; 9():2040. PubMed ID: 30254634
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors.
Costa-Garcia M; Rojas JJ; Ramos MD; Barlabé P; Calvo P; Navas J; Alemany R; Moreno R
Cancer Immunol Immunother; 2024 Jan; 73(1):5. PubMed ID: 38180524
[TBL] [Abstract][Full Text] [Related]
17. Development of a screening method to identify regulators of MICA shedding.
Kishikawa T; Otsuka M; Ohno M; Yoshikawa T; Sato M; Koike K
Biochem Biophys Res Commun; 2015 Oct; 465(4):764-8. PubMed ID: 26299929
[TBL] [Abstract][Full Text] [Related]
18. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
19. HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.
Okita R; Mougiakakos D; Ando T; Mao Y; Sarhan D; Wennerberg E; Seliger B; Lundqvist A; Mimura K; Kiessling R
J Immunol; 2012 Mar; 188(5):2136-45. PubMed ID: 22301547
[TBL] [Abstract][Full Text] [Related]
20. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.
Salih HR; Goehlsdorf D; Steinle A
Hum Immunol; 2006 Mar; 67(3):188-95. PubMed ID: 16698441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
